Evidence map›Paper›PMID 25310094›Full record

ArticlePloS one2014

Immunogenicity evaluation of a rationally designed polytope construct encoding HLA-A*0201 restricted epitopes derived from Leishmania major related proteins in HLA-A2/DR1 transgenic mice: steps toward polytope vaccine.

Negar Seyed, Tahereh Taheri, Charline Vauchy, Magalie Dosset, Yann Godet, Ali Eslamifar, Iraj Sharifi, Olivier Adotevi, Christophe Borg, Pierre Simon Rohrlich and 1 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
4.8field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 31 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Negar SeyedMolecular Immunology and Vaccine Research Lab, Pasteur Institute of Iran, Tehran, Iran.
Tahereh TaheriMolecular Immunology and Vaccine Research Lab, Pasteur Institute of Iran, Tehran, Iran.
Charline VauchyINSERM U1098, Unité Mixte de Recherche, Besançon, France; Etablissement Français du Sang de Bourgogne Franche-Comté, Besançon, France; Université de Franche-Comté, Besançon, France.
Magalie DossetINSERM U1098, Unité Mixte de Recherche, Besançon, France; Etablissement Français du Sang de Bourgogne Franche-Comté, Besançon, France; Université de Franche-Comté, Besançon, France.
Yann GodetINSERM U1098, Unité Mixte de Recherche, Besançon, France; Etablissement Français du Sang de Bourgogne Franche-Comté, Besançon, France; Université de Franche-Comté, Besançon, France.
Ali EslamifarDepartment of Electron Microscopy and Clinical Research, Pasteur Institute of Iran, Tehran, Iran.
Iraj SharifiSchool of Medicine, Leishmaniasis Research Center, Kerman University of Medical Sciences, Kerman, Iran.
Olivier AdoteviINSERM U1098, Unité Mixte de Recherche, Besançon, France; Etablissement Français du Sang de Bourgogne Franche-Comté, Besançon, France; Université de Franche-Comté, Besançon, France; CHRU de Besançon, Service d'Oncologie, Besançon, France.
Christophe BorgINSERM U1098, Unité Mixte de Recherche, Besançon, France; Etablissement Français du Sang de Bourgogne Franche-Comté, Besançon, France; Université de Franche-Comté, Besançon, France; CHRU de Besançon, Service d'Oncologie, Besançon, France.
Pierre Simon RohrlichINSERM U1098, Unité Mixte de Recherche, Besançon, France; Etablissement Français du Sang de Bourgogne Franche-Comté, Besançon, France; Université de Franche-Comté, Besançon, France; CHRU de Besançon, Service de pédiatrie, Besançon, France.
Sima RafatiMolecular Immunology and Vaccine Research Lab, Pasteur Institute of Iran, Tehran, Iran.
Inserm · FRPasteur Institute of Iran · IRKerman University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThere are several reports demonstrating the role of CD8 T cells against Leishmania species. Therefore peptide vaccine might represent an effective approach to control the infection. We developed a rational polytope-DNA construct encoding immunogenic HLA-A2 restricted peptides and validated the processing and presentation of encoded epitopes in a preclinical mouse model humanized for the MHC-class-I and II. METHODS AND

findingsHLA-A*0201 restricted epitopes from LPG-3, LmSTI-1, CPB and CPC along with H-2Kd restricted peptides, were lined-up together as a polytope string in a DNA construct. Polytope string was rationally designed by harnessing advantages of ubiquitin, spacers and HLA-DR restricted Th1 epitope. Endotoxin free pcDNA plasmid expressing the polytope was inoculated into humanized HLA-DRB1*0101/HLA-A*0201 transgenic mice intramuscularly 4 days after Cardiotoxin priming followed by 2 boosters at one week interval. Mice were sacrificed 10 days after the last booster, and splenocytes were subjected to ex-vivo and in-vitro evaluation of specific IFN-γ production and in-vitro cytotoxicity against individual peptides by ELISpot and standard chromium-51 (51Cr) release assay respectively. 4 H-2Kd and 5 HLA-A*0201 restricted peptides were able to induce specific CD8 T cell responses in BALB/C and HLA-A2/DR1 mice respectively. IFN-γ and cytolytic activity together discriminated LPG-3-P1 as dominant, LmSTI-1-P3 and LmSTI-1-P6 as subdominant with both cytolytic activity and IFN-γ production, LmSTI-1-P4 and LPG-3-P5 as subdominant with only IFN-γ production potential.

conclusionsHere we described a new DNA-polytope construct for Leishmania vaccination encompassing immunogenic HLA-A2 restricted peptides. Immunogenicity evaluation in HLA-transgenic model confirmed CD8 T cell induction with expected affinities and avidities showing almost efficient processing and presentation of the peptides in relevant preclinical model. Further evaluation will determine the efficacy of this polytope construct protecting against infectious challenge of Leishmania. Fortunately HLA transgenic mice are promising preclinical models helping to speed up immunogenicity analysis in a human related mouse model.

Indexed as

AnimalsCD8-Positive T-LymphocytesEpitopes, T-LymphocyteHLA-A2 AntigenLeishmania majorLeishmaniasisLeishmaniasis VaccinesMiceMice, TransgenicEpitopes, T-LymphocyteHLA-A*02:01 antigenHLA-A2 AntigenLeishmaniasis Vaccines

Identifiers

PMID25310094
PMCPMC4195657
OpenAlexW2129874731

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.